Literature DB >> 2146801

Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication.

M M Hitt1, F L Graham.   

Abstract

Adenovirus early region 1A(E1A) encodes a heterogeneous family of proteins some of which function as transactivators and are required for efficient viral replication in HeLa cells. We have constructed adenovirus type 5 (Ad 5) mutants in which the E1A transcription unit is placed under the control of either the human beta-actin promoter or the human cytomegalovirus immediate early promoter. The level of E1A expression in cells infected with these mutants was several times higher than that in wild-type virus infections. When the same heterologous promoters were inserted upstream of, but in the opposite orientation to, the E1A transcription unit, the level of expression was greatly reduced with respect to wild-type levels of E1A. Despite this variation of at least 40-fold in the concentration of E1A proteins in infected cells, there was no significant difference between wild-type Ad 5 and any of the mutants in their ability to replicate in HeLa cells. These results suggest that very low levels of E1A proteins are sufficient for virus production in cultured cells and that wild-type Ad 5 produces an amount of E1A in excess of that required.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146801     DOI: 10.1016/0042-6822(90)90134-d

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Authors:  Zeng B Zhu; Angel A Rivera; Sharmila K Makhija; Baogen Lu; Minghui Wang; Miiru Izumi; Robert J Cerfolio; Mariam A Stoff-Khalili; Fen Zhou; Koichi Takayama; Gene P Siegal; David T Curiel
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

2.  Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.

Authors:  Erkko Ylösmäki; Tanja Hakkarainen; Akseli Hemminki; Tapio Visakorpi; Raul Andino; Kalle Saksela
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

3.  Sensitivity of subgroup F adenoviruses to interferon.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  The adenovirus E1A transforming protein activates the proliferating cell nuclear antigen promoter via an activating transcription factor site.

Authors:  G F Morris; M B Mathews
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Authors:  M I Gorziglia; M J Kadan; S Yei; J Lim; G M Lee; R Luthra; B C Trapnell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.

Authors:  Justyna Leja; Berith Nilsson; Di Yu; Elisabet Gustafson; Göran Akerström; Kjell Oberg; Valeria Giandomenico; Magnus Essand
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

Review 8.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

9.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

Authors:  G W Wilkinson; A Akrigg
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

10.  Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Authors:  Ilya V Ulasov; Matthew A Tyler; Angel A Rivera; Dirk M Nettlebeck; Joanne T Douglas; Maciej S Lesniak
Journal:  J Med Virol       Date:  2008-09       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.